Glycobiology: drifting toward polymer perfection.

Area of Science:

• Biochemistry
• Biotechnology
• Therapeutic Development

Background:

• Polysialic acid (PSA) modification of proteins and cells is a developing therapeutic strategy.
• Current methods using polysialyltransferases produce PSA polymers of suboptimal, variable lengths.
• This variability limits the efficacy of PSA-based therapeutic reagents.

Purpose of the Study:

• To address the limitations of current polysialyltransferase activity.
• To develop a method for producing homogeneous PSA polymers for therapeutic use.
• To explore enzyme engineering via neutral genetic drift for controlled PSA synthesis.

Main Methods:

• Utilizing neutral genetic drift to engineer polysialyltransferase variants.
• Characterizing the enzymatic activity and product polymer lengths of engineered variants.
• Assessing the homogeneity and suitability of synthesized PSA for therapeutic applications.

Main Results:

• Successful generation of polysialyltransferase variants with altered catalytic properties.
• Demonstration of controlled synthesis of PSA polymers with specific, consistent lengths.
• Identification of engineered variants capable of producing PSA optimal for therapeutic reagents.

Conclusions:

• Neutral genetic drift is an effective strategy for engineering polysialyltransferases.
• This approach enables the production of homogeneous, therapeutically relevant polysialic acid.
• The developed enzyme variants represent a significant advancement for PSA-based therapeutics.